Mao, Z. and Ong, A.C.M. (2009) Peroxisome proliferator-activated receptor gamma agonists in kidney disease - future promise, present fears. Nephron Clinical Practice, 112 (4). pp. 230-241. ISSN 1660-2110
Abstract
The peroxisome proliferator-activated receptor superfamily (PPARs) comprises a class of nuclear receptors with significant effects in regulating multiple cellular pathways. Much research and clinical interest has surrounded the PPAR-Y isoform because of its key role in the transcriptional regulation of metabolic pathways and the efficacy of thiazolidinediones, the most clinically used PPAR-Y agonist, in the management of type 2 diabetes mellitus. In this review, we discuss the pathogenic role of PPAR-Y in experimental models of kidney disease, clinical trials of thiazolidinediones in diabetic and non-diabetic kidney disease, recent safety concerns surrounding PPAR-Y agonists and reflect on their potential use in 'orphan' kidney diseases.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Keywords: | PPAR-Y agonists; Thiazolidinediones; Kidney disease; Diabetes mellitus |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) > Clinical Sciences Division North (Sheffield) > Sheffield Kidney Institute |
Depositing User: | Miss Anthea Tucker |
Date Deposited: | 11 Aug 2009 08:58 |
Last Modified: | 11 Aug 2009 09:00 |
Published Version: | http://dx.doi.org/10.1159/000224789 |
Status: | Published |
Publisher: | Karger |
Refereed: | Yes |
Identification Number: | 10.1159/000224789 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:9071 |